Health Care • Biotechnology: Pharmaceutical Preparations
$109.31 ▼ -3.27
(-2.90%)
MKT CAP: $24.70B • VOL: 4.24M
52W L $90 52W H $213
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$92
MEDIAN
$122
MEAN
$125
HIGH
$149
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE INSM TAPE
INSM // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $132.27 | $125.71 | 2025-02-14 | $99.47 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $137.73 | $128.99 | 2025-02-06 | $102.75 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $124.61 | $120.24 | 2025-01-29 | $104.94 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $111.50 | — | 2025-01-17 | $107.12 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $96.19 | $103.84 | 2025-01-09 | $97.29 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $130.08 | $113.68 | 2024-12-18 | $95.10 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $106.03 | $110.40 | 2024-12-04 | $101.66 | -4.3% | 48% | C |